This session will focus on the progress in molecular profiling of children’s cancers and how this is informing treatment decisions. Speakers will cover the Genomics England and StratMedPaeds initiatives, and discuss how molecular profiling and molecular tumour boards are being used to inform clinically relevant therapies for patients through platform trials such as eSMART, HEM-iSMART, DETERMINE and TAPISTRY. An overview of the Children’s Cancer Priority Setting Partnership (overseen by James Lind Alliance) will also be provided, and a discussion on the Non-Hodgkin’s Lymphoma portfolio of trials, and the NCRI Groups key strategic aims in this area. There will be an opportunity for the audience to ask questions throughout the session.
- Dr Julia Chisholm – Chair of the NCRI Children’s Group
- Dr Lynley Marshall – The Royal Marsden NHS Foundation Trust
- Ms Loveday Langton – NCRI Consumer
- Dr Bob Phillips – The University of York
- Dr Mary Taj – The Royal Marsden NHS Foundation Trust
- Dr Michael Hubank – The Institute of Cancer Research
- Professor Louis Chesler – The Institute of Cancer Research
2 category 1 (external) CPD for this session has been approved by the Federation of the Royal Colleges of Physicians. CPD Certificates will be sent to delegates automatically up to 10 days after the event date.
Who should attend?
Anyone interested or working in childhood cancer research including patients and carers formally involved in research, scientists, medical/clinical oncologists, surgeons, early career researchers, nurses, allied health professionals, PhD and undergraduate students, research teams and research managers/funders.